Expand VIR Menu
VIR MENU

VIR Latest Press Releases

-- June 10, 2026 --

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors Business Wire 4:05 PM

-- May 18, 2026 --

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 Business Wire 4:05 PM

-- May 14, 2026 --

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies Globe Newswire 10:55 AM

-- May 6, 2026 --

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results Business Wire 4:05 PM

-- May 5, 2026 --

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference Business Wire 4:05 PM

-- April 23, 2026 --

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results Business Wire 4:05 PM

-- April 16, 2026 --

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer Business Wire 8:05 AM

-- April 13, 2026 --

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Business Wire 8:05 AM

-- February 26, 2026 --

Vir Biotechnology to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- February 25, 2026 --

Vir Biotechnology Announces Pricing of Public Offering of Common Stock Business Wire 10:31 PM

-- February 24, 2026 --

Vir Biotechnology Announces Proposed Public Offering of Common Stock Business Wire 4:05 PM
Biotech and Big Tech Drive the Morning Narrative Globe Newswire 10:17 AM

-- February 23, 2026 --

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 5:14 PM
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Business Wire 5:02 PM
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer PRNewswire 5:00 PM

-- February 9, 2026 --

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:05 PM
Market Data Delayed 15 Minutes